SNSS - Sunesis Pharmaceuticals Inc. (SNSS) CEO Dayton Misfeldt on Q2 2020 Results - Earnings Call Transcript
Sunesis Pharmaceuticals, Inc. (SNSS)
Q2 2020 Earnings Conference Call
August 11, 2020 4:30 PM ET
Company Participants
Par Hyare - Investor Relations
Dayton Misfeldt - Interim Chief Executive Officer
Judy Fox - Chief Scientific Officer, Executive Vice President, Research & Development
Conference Call Participants
Hartaj Singh - Oppenheimer
Marc Frahm - Cowen and Company
Jim Birchenough - Wells Fargo Securities
Presentation
Operator
Ladies and gentlemen, thank you for standing by and welcome to the Second Quarter 2020 Sunesis Pharmaceuticals Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’